| Molecular Formula | C24H29NO5 |
| Molar Mass | 411.49 |
| Density | 1.151±0.06 g/cm3(Predicted) |
| Boling Point | 656.9±55.0 °C(Predicted) |
| Solubility | 10 mM in DMSO |
| pKa | 4.72±0.10(Predicted) |
| Storage Condition | Sealed in dry,Store in freezer, under -20°C |
| Use | Intermediate |
| In vitro study | Sacubitril (AHU-377) is a single molecule that is comprised of molecular moieties of valsartan, an ARB, and Sacubitril (AHU-377), a neprilysin inhibitor (1:1 ratio). Sacubitril (AHU-377) is converted by enzymatic cleavage of the ethyl ester into the active neprilysin inhibiting metabolite LBQ657. The inactive NEPi precursor, Sacubitril (AHU-377), does not inhibit collagen accumulation in fibroblasts nor cardiac myocyte hypertrophy. In cardiac fibroblasts, the active NEPi LBQ657 had no discernible effects. In contrast, LBQ657 modestly inhibits cardiac myocyte hypertrophy. |
| In vivo study | In humans, Sacubitril (AHU-377) (t max 0.5-1.1 h) are absorbed quickly. Sacubitril (AHU-377) is converted rapidly into LBQ657 with its t max being reached in 1.9-3.5 h. Mean t 1/2 values for the biologically active LBQ657 is 9.9-11.1 h. In vehicle-treated dogs, ANF increases urinary sodium excretion from 17.3±3.6 to 199.5±18.4 pequivkglmin. This effect is potentiated significantly in animals which receive Sacubitril (AHU-377). Urinary volume is also potentiated in animals which receive an iv administration of Sacubitril (AHU-377). |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.43 ml | 12.151 ml | 24.302 ml |
| 5 mM | 0.486 ml | 2.43 ml | 4.86 ml |
| 10 mM | 0.243 ml | 1.215 ml | 2.43 ml |
| 5 mM | 0.049 ml | 0.243 ml | 0.486 ml |